Mangoceuticals Shares Soar 50% After 336% Sales Surge for $99 TRT Program
Mangoceuticals reported its $99/month injectable TRT subscription program saw month-over-month sales jump 336% and acquisition costs drop 54% since mid-December, fueling a 50% share rally on Friday. Management highlighted telehealth-first distribution and plans to expand TRT offerings, targeting a $2.11–2.2B market with both injectable and oral therapies.
1. Explosive Sales Growth for Injectable TRT
Since launching its $99/month injectable testosterone replacement therapy in mid-December, Mangoceuticals has recorded a 336% increase in month-over-month sales, underscoring rapid customer adoption of its subscription model.
2. Cost Efficiency Improvements
Over the same period, the company achieved a 54% reduction in customer acquisition costs, as telehealth-driven marketing and streamlined digital enrollment drove more cost-effective patient sign-ups.
3. Telehealth-First Strategy and Market Opportunity
CEO Jacob Cohen emphasized the value of the telehealth-first approach to men’s hormone health, noting plans to broaden offerings to include the PRIME oral capsule powered by Kyzatrex and capitalize on a global TRT market projected at $2.11–2.2 billion in 2025.
4. Share Price Reaction
Shares jumped roughly 50% on Friday, trading near $0.50, as investors responded to strong early traction in the injectable TRT business and the company’s outlook for sustained subscription-driven growth.